Developing new vaccines to prevent chlamydia infections in men
Investigation of novel chlamydia vaccines in male infection models and sexual transmission challenges
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · NIH-11000254
This study is testing new vaccines to help protect against Chlamydia, a common sexually transmitted infection, especially focusing on how it affects men and the risk of spreading it, using a special method that could boost the immune response.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR (nih funded) |
| Locations | 1 site (ALBUQUERQUE, UNITED STATES) |
| Trial ID | NIH-11000254 on ClinicalTrials.gov |
What this research studies
This research focuses on creating novel vaccines to combat Chlamydia trachomatis, the bacteria responsible for the most common bacterial sexually transmitted infection. The study aims to address the gap in understanding male infections and their role in transmission, particularly in the context of anorectal infections. By using innovative bacteriophage virus-like particles as a vaccine platform, the research seeks to enhance immune responses and reduce the risk of reinfection. The approach involves testing these vaccines in male infection models to evaluate their effectiveness in preventing transmission.
Who could benefit from this research
Good fit: Ideal candidates for this research include men who are at risk of chlamydia infections, particularly those with a history of sexually transmitted infections.
Not a fit: Patients who are not sexually active or those who have already been effectively treated for chlamydia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that prevent chlamydia infections, reducing the incidence of severe health complications associated with the disease.
How similar studies have performed: While there has been significant research on chlamydia treatment, the development of vaccines using this specific approach is relatively novel and has not been extensively tested.
Where this research is happening
ALBUQUERQUE, UNITED STATES
- UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR — ALBUQUERQUE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JAMUS, ANDZOA — UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
- Study coordinator: JAMUS, ANDZOA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.